Sorafenib: Scientific Rationales for Single-Agent and Combination Therapy in Clear-Cell Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib: Scientific Rationales for Single-Agent and Combination Therapy in Clear-Cell Renal Cell Carcinoma

Published:2005-12 Issue:3 Volume:4 Page:167-174
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Gollob Jared A.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference44 articles.

1. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma;McDermott;J Clin Oncol,2005

2. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie;Negrier;N Engl J Med,1998

3. Molecular basis of the VHL hereditary cancer syndrome;Kaelin;Nat Rev Cancer,2002

4. The von Hippel-Lindau tumor suppressor gene and kidney cancer;Kaelin;Clin Cancer Res,2004

5. Tumour suppression by the human von Hippel-Lindau gene product;Iliopoulos;Nat Med,1995

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer;Translational Oncology;2024-03

2. Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy;Journal of Cellular Physiology;2019-06-29

3. Prostaglandin E 1 reduces the keratinocyte toxicity of sorafenib by maintaining signal transducer and activator of transcription 3 (STAT3) activity and enhancing the cAMP response element binding protein (CREB) activity;Biochemical and Biophysical Research Communications;2017-04

4. Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types;Resistance to Targeted Anti-Cancer Therapeutics;2016

5. Tokio Rationale and Protocol: A Phase II Study to Evaluate the Activity and Safety of Third-line Tyrosine Kinase Inhibitor after 2 Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma;Tumori Journal;2015-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3